Identifying Mechanisms Of Resistance To Novel Hormonal Agents In Patients With Castrate-resistant Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$420,004.00
Summary
I am a medical oncologist focused on prostate cancer, a disease which kills over 3000 Australian men every year. Recent studies have shown that new hormone treatments help men with advanced prostate cancer live longer. Unfortunately, while these drugs are effective when first started, prostate cancers eventually become resistant to them and start growing again. By looking at why these drugs stop working, I hope to find better treatments for Australian men with advanced prostate cancer.
Novel Therapeutic Strategies For Pancreatic Cancer Using Next Generation Sequencing
Funder
National Health and Medical Research Council
Funding Amount
$354,892.00
Summary
Dr David Chang is a surgeon scientist who specialises in the treatment of pancreatic cancer. His research focus is on the development and implementation of novel therapeutic strategies for pancreatic cancer. He aims to achieve this by utilising novel biomarkers that have the ability to forecast prognosis and response to treatments. Ultimately, this will lead to the “individualised” treatment for each patient.
Determining The Clinical Relevance Of Intratumour Heterogeneity In Breast Cancer And Its Relationship To Metastases Formation
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Breast cancer metastasis is generally an incurable disease, yet it is not well-understood. This project aims to understand how cancer metastasises by using a novel and unique approach of analysing multiple regions from matched primary and metastatic tumours from breast cancer patients. Expected outcomes include identifying predictors of treatment resistance and resultant personalised management and therapeutic strategies to improve survival outcomes of breast cancer patients.
Next-generation Glioblastoma Multiforme Therapies Based On Multistage Delivery Nanovectors
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Nanomedicine provides novel therapies with enhanced treatment success and reduced side effects, which improve the patient’s quality of life. Drug delivery systems that are able to treat highly drug-resistant tumours such as glioblastoma multiforme (GBM) are a key target for nanomedicine-based therapies. We will investigate a new GBM treatment by developing a multistage delivery nanovector to selectively carry and release a combination of chemical and physical therapeutics.
The Role Of The Alimentary Microbiome In The Development Of Mucositis
Funder
National Health and Medical Research Council
Funding Amount
$302,123.00
Summary
Mucositis is a debilitating side effect of cancer treatment, which is currently not treatable or preventable, due to a lack of understanding of how mucositis develops. Previous research has shown that microbes are involved in the development of mucositis in animal models. This project will determine if bacteria in the mouth and intestine play a role in the development of mucositis in patients, and if changes are easily detected, to allow for a more 'personalised' approach to manage mucositis.
Toll-like Receptor 2 Signalling As A Potential Therapeutic Target In Gastric Cancer
Funder
National Health and Medical Research Council
Funding Amount
$323,091.00
Summary
Stomach cancer is the fourth most deadly cancer in the world. Stomach cancer is closely linked with inflammation, and we have shown that a key inflammatory molecule, called toll-like receptor 2 (TLR2), can drive the development of stomach cancer. However, this occurs in a non-inflammatory manner. My research aims to understand how TLR2 is involved in the progression of stomach cancer, with the ultimate goal to find an early biomarker of disease, and to develop better therapies.
Targeting The Epithelial-to-mesenchymal Transition In Basal-like Breast Cancers
Funder
National Health and Medical Research Council
Funding Amount
$348,823.00
Summary
Metastasis accounts for over 90% of deaths due to cancer worldwide. I aim to uncover the signals, which drive cancer cells to distant sites leading to metastatic tumour growth. Although the efficacy of current therapeutics is improving, they are unable to counteract tumour spread and relapses that are common with many cancers. My research will focus on understanding the events that lead to metastasis thus enabling us to develop better therapies for aggressive cancers.
Identifying Novel Genome Instability Signatures In Cancer
Funder
National Health and Medical Research Council
Funding Amount
$320,891.00
Summary
Cancer is the single biggest clinical problem facing the world. An underlying hallmark of cancer is the accumulation of errors in the genetic information of a cell which arises through genomic instability. This research project aims to investigate novel molecules identified by our screening that function in response to genomic instability in cancer. This study is expected to define roles for each molecule in the maintenance of genomic stability and predict for patient diagnosis and outcome.
Identifying The Molecular Mechanisms Of Synergistic And Antagonistic Drug-drug Interactions In Combination Chemotherapies
Funder
National Health and Medical Research Council
Funding Amount
$412,685.00
Summary
Drug combinations in chemotherapy hold promise for more effective treatments and for overcoming drug resistance, but the search for effective combinations is challenging. The combination therapy R-CHOP is often curative for Diffuse Large B-cell Lymphoma (DLBCL). Both cellular drug interactions and evolutionary drug interactions will be quantified in DLBCL cells, to understand the defining features of effective combinations and guide the future rational design of combinations.